Advertisement

PharmacoEconomics & Outcomes News

, Volume 841, Issue 1, pp 1–1 | Cite as

ICER: semaglutide less cost effective vs empagliflozin in T2DM

News item
  • 8 Downloads

Reference

  1. Institute for Clinical and Economic Review. ICER Report Finds Oral GLP-1 Semaglutide, at Estimated Net Price, Less Cost-Effective Than SGLT-2 Competitor Empaglifozin as Add-on Therapy for Type 2 Diabetes. Internet Document : 1 Nov 2019. Available from: URL: https://icer-review.org/announcements/semaglutide_evidence_report/

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations